Vanessa Elharrar
Overview
Explore the profile of Vanessa Elharrar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
5078
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grant R, Mannheimer S, Hughes J, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, et al.
Clin Infect Dis
. 2018 Feb;
66(11):1712-1721.
PMID: 29420695
Background: Nondaily dosing of oral preexposure prophylaxis (PrEP) may provide equivalent coverage of sex events compared with daily dosing. Methods: At-risk men and transgender women who have sex with men...
2.
Bekker L, Roux S, Sebastien E, Yola N, Amico K, Hughes J, et al.
Lancet HIV
. 2017 Oct;
5(2):e68-e78.
PMID: 28986029
Background: The relative feasibility and acceptability of daily versus non-daily dosing of oral HIV pre-exposure prophylaxis (PrEP) among women are unknown. We aimed to investigate the feasibility of non-daily PrEP...
3.
Riddler S, Husnik M, Ramjee G, Premrajh A, Tutshana B, Pather A, et al.
PLoS One
. 2017 Jun;
12(6):e0178594.
PMID: 28658251
Background: Little is known regarding HIV disease outcomes among individuals who become infected with HIV while receiving antiretroviral medications for prevention. We compared HIV disease parameters among women who seroconverted...
4.
El-Sadr W, Donnell D, Beauchamp G, Hall H, Torian L, Zingman B, et al.
JAMA Intern Med
. 2017 Jun;
177(8):1083-1092.
PMID: 28628702
Importance: Achieving linkage to care and viral suppression in human immunodeficiency virus (HIV)-positive patients improves their well-being and prevents new infections. Current gaps in the HIV care continuum substantially limit...
5.
Safren S, Hughes J, Mimiaga M, Moore A, Friedman R, Srithanaviboonchai K, et al.
J Int AIDS Soc
. 2016 Oct;
19(1):21096.
PMID: 27687145
Introduction: Successful global treatment as prevention (TasP) requires identifying HIV-positive individuals at high risk for transmitting HIV, and having impact via potential infections averted. This study estimated the frequency and...
6.
Riddler S, Husnik M, Gorbach P, Levy L, Parikh U, Livant E, et al.
HIV Clin Trials
. 2016 Jul;
17(5):204-11.
PMID: 27465646
Background: As the effect of biomedical prevention interventions on the natural history of HIV-1 infection in participants who seroconvert is unknown, the Microbicide Trials Network (MTN) established a longitudinal study...
7.
Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al.
N Engl J Med
. 2016 Jul;
375(9):830-9.
PMID: 27424812
Background: An interim analysis of data from the HIV Prevention Trials Network (HPTN) 052 trial showed that antiretroviral therapy (ART) prevented more than 96% of genetically linked infections caused by...
8.
Amico K, Wallace M, Bekker L, Roux S, Atujuna M, Sebastian E, et al.
AIDS Behav
. 2016 Jun;
21(5):1361-1375.
PMID: 27317411
Placebo-controlled trials of pre-exposure prophylaxis (PrEP) have reported challenges with study-product uptake and use, with the greatest challenges reported in studies with young women in sub-Saharan Africa. We conducted a...
9.
Hendrix C, Andrade A, Bumpus N, Kashuba A, Marzinke M, Moore A, et al.
AIDS Res Hum Retroviruses
. 2015 Sep;
32(1):32-43.
PMID: 26414912
Oral preexposure prophylaxis (PrEP) trials report disparate efficacy attributed to variable adherence. HPTN 066 was conducted to establish objective, quantitative benchmarks for discrete, regular levels of adherence using directly observed...
10.
Magidson J, Li X, Mimiaga M, Moore A, Srithanaviboonchai K, Friedman R, et al.
AIDS Behav
. 2015 Aug;
20(4):699-709.
PMID: 26246068
Successful biomedical prevention/treatment-as-prevention (TasP) requires identifying individuals at greatest risk for transmitting HIV, including those with antiretroviral therapy (ART) nonadherence and/or 'amplified HIV transmission risk,' defined as condomless sex with...